2016 PharmSource - Bio/Pharma CapEx Trends in Industry Growth

Albany, New York, December 24, 2016: A recent report focusing on the PharmSource industry has been added to the vast database of Market Research Hub (MRH). It is entitled as “PharmSource - Bio/Pharma CapEx Trends 2016”. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, its clear that bio/pharma companies would rather make than buy.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=903182

According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=903182

Scope

- Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
- It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
- It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.

Reasons to buy

- The 16-page report provides important insight that you wont find in any other source. This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Browse Full Info with TOC: http://www.marketresearchhub.com/report/pharmsource-biopharma-capex-trends-2016-report.html

Table of Contents

• Executive Summary 1
• Introduction 2
• CapEx Overview 3
• CapEx Relative to Other Financial Indicators 6
• Nature of Capital Expenditure - What Is Being Built 8
• What It Means 10
• Appendix 12
• Recently Announced and Completed Investments by Global Bio/Pharma Companies 12
• Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies 14
• Selected CapEx Investments by Generic Companies 2014 Onwards 15

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/

This release was published on openPR.